Latest updates for Alan Cassels

Fresh curated links around Alan Cassels are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Why Observational Studies Lie to You
  • The conflict of interest that discloses as nothing
  • How supplement fraud slips past a certificate of analysis

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

activistpost.com /1 week ago

Why Observational Studies Lie to You

If you’ve spent five minutes paying attention to medical news, you’ve undoubtedly seen the headlines: “People who take statins have 30% fewer heart attacks!” or “Breast cancer scre...

Read source
kevinmd.com /4 weeks ago

The conflict of interest that discloses as nothing

With 66 percent of U.S. adults, some 131 million people, now taking prescription drugs, and with Medicare drug spending running into the hundreds of billions, it is worth asking ho...

Read source
kevinmd.com /1 month ago

How supplement fraud slips past a certificate of analysis

In our first article, we discussed the international regulatory clash between U.S. supplement mandates (21 CFR 111) and foreign food and supplement laws. This gap can lead to inade...

Read source
moneytalksnews.com /1 month ago

Is Your Second Prescription Treating Your First One? See If You’re Part of a Prescription Cascade

Researchers tracked 2.3 million seniors and found one pill routinely leading to another. Three chains start with drugs you know.

Read source
pharmexec.com /1 month ago

<![CDATA[The Ron Lanton Report: What Are We Doing This All For?]]>

Read source
kirkusreviews.com /1 month ago

THE AGE OF CURES

Werth, whose books include The Billion-Dollar Molecule (1994), opens with the 1918 Spanish flu pandemic, which did not spare the U.S., whose doctors wrote millions of prescriptions...

Read source
kevinmd.com /2 weeks ago

Pharmacy benefit managers and the price no one can see

A physician writes a prescription believing the clinical decision has been made. In reality, another decision-making process is just beginning. Between the prescription and the pat...

Read source
realclearinvestigations.com /1 month ago

Bad Medicine: Billions Wasted on Unnecessary Treatments

Read source
biopharmadive.com /1 month ago

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiov...

Read source
pharmexec.com /1 week ago

<![CDATA[Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts]]>

Read source
nytimes.com /1 month ago

How Did a Heart Drug With So Much Promise Fall So Flat?

Cardiologists are struggling to figure out why a drug that should have prevented heart attacks didn’t work at all.

Read source
kevinmd.com /3 weeks ago

Direct-to-consumer drug ads sell lifestyle, not physiology

Direct-to-consumer drug advertising has changed dramatically over the past decade. What began as cautious messaging about serious medications has evolved into lifestyle marketing:...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: David Samra Calls For Novartis Board Shake-Up]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Wendy Short Bartie: Reputation as Currency]]>

Read source
goodmenproject.com /4 days ago

Canada Is Losing the Race for Clinical Trials – and Patients Are Paying the Price

An opinion piece argues that fragmented approvals, slow recruitment and delayed drug access are weakening Canada’s clinical trial sector and limiting patient opportunities. The pos...

Read source
drugs.com /1 month ago

How Much Of A Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages

MONDAY, Aug. 24, 2026 — Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide...

Read source
drugs.com /1 month ago

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don't Qualify

WEDNESDAY, Aug. 26, 2026 — In January, Jeff La Marca got a prescription for the popular weight loss drug Zepbound. But he couldn’t afford the $750 monthly price tag. “I thought, ‘T...

Read source
pharmexec.com /1 month ago

<![CDATA[The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang]]>

Read source
pharmexec.com /1 week ago

<![CDATA[AI Gut Check ]]>

Read source
pharmexec.com /1 month ago

<![CDATA[What the Peptide Advisory Vote Actually Means: Q&A with James LaValle]]>

Read source
medcitynews.com /1 month ago

The Trials Were Always There — Patients Just Couldn’t Find Them

This structural problem calls for a structural solution, requiring no new science, regulation, or data.  The post The Trials Were Always There — Patients Just Couldn’t Find Them ap...

Read source
pharmexec.com /1 month ago

<![CDATA[Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations]]>

Read source
jewishjournal.com /1 month ago

Israel’s Clinical Trial Illusion: Testing Drugs Is Not the Same as Capturing Economic Value

Clinical trial statistics tell us where investigational drugs are tested. They do not tell us who owns the assets, who uses the evidence to obtain regulatory approvals or who captu...

Read source
nytimes.com /1 month ago

The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists

Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Alan Cassels

feeds.feedburner.com

Recent coverage from public sources
Public source

jewishjournal.com

Recent coverage from public sources
Public source

rss.nytimes.com

Recent coverage from public sources
Public source

realclearpolitics.com

Recent coverage from public sources
Public source

feeds.feedburner.com

Recent coverage from public sources
Public source

goodmenproject.com

Recent coverage from public sources
Public source